Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ).
Shanghai Fosun Pharmaceutical announced that its subsidiary, Hunan Dongting Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing registration of Oxazepam Tablets. This development is significant as it marks an expansion in Fosun Pharma’s product offerings, potentially enhancing its market position and providing new opportunities for growth in the pharmaceutical sector.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a major player in the pharmaceutical industry, based in China. The company focuses on the development and manufacturing of a wide range of pharmaceutical products, with an emphasis on innovation and market expansion.
YTD Price Performance: -8.22%
Average Trading Volume: 1,184
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $7.73B
Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.
